CSL Ltd ADR CSLLY
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
CSL is the one of largest global biotech companies. Products are focused on two key areas – protein science therapies such as plasma-derived immunoglobulins for the treatment of immune deficiencies and neurological conditions, in its CSL Behring division, and influenza vaccines, in its Seqirus division. CSL has a strong research and development track record. The portfolio and pipeline include non-plasma products as the company broadens its biotech scope. Originally formed in Australia as a commonwealth-owned entity, CSL now earns half its revenue in North America and a quarter in Europe.
Parkville, VIC, 3052, Australia